Schrodinger Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.

Benzinga · 05/07 21:46

Schrodinger (NASDAQ:SDGR) Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.